Results 41 to 50 of about 399,293 (360)

Primary CNS Lymphoma [PDF]

open access: yes, 2014
Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system is an aggressive malignancy that exhibits unique biological features and characteristic clinical behaviour, with overall long-term survival rates of around 20–40 %.
Cwynarski, K, Fox, CP, Phillips, EH
core   +1 more source

Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): A feasibility study [PDF]

open access: yes, 2006
Background: Concurrent chemoradiotherapy has improved survival in inoperable stage III non-small cell lung cancer (NSCLC). This phase I trial was performed in order to establish a dose recommendation for oral vinorelbine in combination with cisplatin and
Clamon G   +17 more
core   +1 more source

Enhancement of chemotherapy using oncolytic virotherapy: Mathematical and optimal control analysis [PDF]

open access: yesMath. Biosci. Eng. 15 (2018), no. 6, 1435--1463, 2018
Oncolytic virotherapy (OV) has been emerging as a promising novel cancer treatment that may be further combined with the existing therapeutic modalities to enhance their effects. To investigate how OV could enhance chemotherapy, we propose an ODE based model describing the interactions between tumour cells, the immune response, and a treatment ...
arxiv   +1 more source

Bayesian modelling of response to therapy and drug-sensitivity in acute lymphoblastic leukemia [PDF]

open access: yesarXiv, 2023
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy involving the abnormal proliferation of immature lymphocytes, accounting for most pediatric cancer cases. ALL management in children has seen great improvement in the last decades thanks to better understanding of the disease leading to improved treatment strategies evidenced ...
arxiv  

Advances in the management of HPV-related oropharyngeal cancer [PDF]

open access: yes, 2019
Patients with human papillomavirus- (HPV-) related oropharyngeal squamous cell carcinoma (OPSCC) have a better prognosis than HPV-negative OPSCC when treated with standard high-dose cisplatin-based chemoradiotherapy.
Brugnoletti, O.   +6 more
core   +1 more source

A Retrospective Analysis using Deep-Learning Models for Prediction of Survival Outcome and Benefit of Adjuvant Chemotherapy in Stage II/III Colorectal Cancer [PDF]

open access: yesarXiv, 2021
Most early-stage colorectal cancer (CRC) patients can be cured by surgery alone, and only certain high-risk early-stage CRC patients benefit from adjuvant chemotherapies. However, very few validated biomarkers are available to accurately predict survival benefit from postoperative chemotherapy.
arxiv  

Higher cytotoxic activities of CD8+ T cells and natural killer cells from peripheral blood of early diagnosed lung cancer patients

open access: yesBMC Immunology, 2023
Introduction Cytotoxic (CD8+) and natural killer (NK) cells play critical roles in anti-tumor immunity. Dysfunction in these cells is considered as one of the extrinsic mechanisms for tumor relapse.
Mohamed Labib Salem   +2 more
doaj   +1 more source

Combination Chemotherapy Optimization with Discrete Dosing [PDF]

open access: yesarXiv, 2021
Chemotherapy is one of the primary modalities of cancer treatment. Chemotherapy drug administration is a complex problem that often requires expensive clinical trials to evaluate potential regimens. One way to alleviate this burden and better inform future trials is to build reliable models for drug administration.
arxiv  

The effect of dietary intake changes on nutritional status in acute leukemia patients after first induction chemotherapy [PDF]

open access: yes, 2015
This study aimed to evaluate how changes in dietary intake among acute lymphoblastic and acute myeloid leukaemia (ALL and AML) patients affect nutritional status after the first induction chemotherapy.
Chan, Yoke Mun   +6 more
core   +1 more source

Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era

open access: yesTherapeutics and Clinical Risk Management, 2020
Zhen Su,1,* Guo-rong Zou,1,* Jie Tang,1 Xiu Yue Li,1 Fang-Yun Xie2 1Panyu Central Hospital, Cancer Institute of Panyu, Guangzhou, People’s Republic of China; 2Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, State Key ...
Su Z, Zou G, Tang J, Li XY, Xie FY
doaj  

Home - About - Disclaimer - Privacy